TheAnonymousBanker

[BMY] SELL SETUP

Short
TheAnonymousBanker Mis à jour   
NYSE:BMY   Bristol-Myers Squibb Company
BMY
57
bmy
Simple Sell Setup with a interesting Risk Ratio ( > 1:3 ). Details below or on chart:

FUNDAMENTAL NOTE:
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.


SETUP MODE
---------------------------------------
# ACCOUNT BALANCE: 10K #
---------------------------------------

- SELL AREA: 55.60/55.95
- STOP LOSS: 56.85
- TARGET: 52.00/51.50
=====================

MONEY MANAGEMENT
---------------------------------------
# SELL: 10.000$ (Risk: 3%) #
---------------------------------------

- SIZE: 200 lots/shares
- POTENTIAL LOSS: 300$
- POTENTIAL GAIN: 1.100$


TRADER NOTE:
Minimun Account: 1.000$ (20 lots/shares)


...Thank you for your support and trade with care!
Commentaire:
...pending order
Commentaire:
Commentaire:
Rebound in play... follow our idea!
Trade fermée: cible de profit atteinte:

🔔 2024 Forex Long Term Analysis:
🌐 anonymousbanker.org/
🥇 Crypto Exchange:
🌐 bit.ly/CryptExchange

Analysis made with 💝
By Anonymous Banker
A TradingView Fan since 2015
Clause de non-responsabilité

Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.